CCL2 and diabetic kidney disease: In a model of streptozotocin-induced diabetes in Sprague–Dawley rats, bFGF delayed the progression of diabetic nephropathy, possibly by inhibiting NF-κB and silencing of TGF-β1, MCP-1, IL-6, and IL-1β [59].